Annual Accounts Payable
$364.90 M
+$61.00 M+20.07%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual accounts payable is currently $364.90 million, with the most recent change of +$61.00 million (+20.07%) on 31 December 2023. During the last 3 years, it has risen by +$209.80 million (+135.27%). VRTX annual accounts payable is now at all-time high.VRTX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$395.80 M
+$67.90 M+20.71%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly accounts payable is currently $395.80 million, with the most recent change of +$67.90 million (+20.71%) on 30 September 2024. Over the past year, it has increased by +$19.90 million (+5.29%). VRTX quarterly accounts payable is now at all-time high.VRTX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +20.1% | +5.3% |
| 3 y3 years | +135.3% | +209.6% |
| 5 y5 years | +228.8% | +327.8% |
VRTX Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +135.3% | at high | +211.9% |
| 5 y | 5 years | at high | +316.5% | at high | +351.8% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Vertex Pharmaceuticals Incorporated Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $395.80 M(+20.7%) |
| June 2024 | - | $327.90 M(-6.7%) |
| Mar 2024 | - | $351.40 M(-3.7%) |
| Dec 2023 | $364.90 M(+20.1%) | $364.90 M(-2.9%) |
| Sept 2023 | - | $375.90 M(+3.6%) |
| June 2023 | - | $363.00 M(+12.3%) |
| Mar 2023 | - | $323.20 M(+6.4%) |
| Dec 2022 | $303.90 M(+55.8%) | $303.90 M(+139.5%) |
| Sept 2022 | - | $126.90 M(-35.9%) |
| June 2022 | - | $198.00 M(+14.1%) |
| Mar 2022 | - | $173.60 M(-11.0%) |
| Dec 2021 | $195.00 M(+25.7%) | $195.00 M(+52.5%) |
| Sept 2021 | - | $127.86 M(+0.3%) |
| June 2021 | - | $127.53 M(-0.2%) |
| Mar 2021 | - | $127.84 M(-17.6%) |
| Dec 2020 | $155.10 M(+77.0%) | $155.10 M(+43.9%) |
| Sept 2020 | - | $107.79 M(+6.2%) |
| June 2020 | - | $101.45 M(+0.7%) |
| Mar 2020 | - | $100.70 M(+14.9%) |
| Dec 2019 | $87.61 M(-21.1%) | $87.61 M(-5.3%) |
| Sept 2019 | - | $92.53 M(+20.1%) |
| June 2019 | - | $77.05 M(-6.3%) |
| Mar 2019 | - | $82.26 M(-25.9%) |
| Dec 2018 | $110.99 M(+50.0%) | $110.99 M(+20.4%) |
| Sept 2018 | - | $92.15 M(+11.0%) |
| June 2018 | - | $83.03 M(+12.1%) |
| Mar 2018 | - | $74.06 M(+0.1%) |
| Dec 2017 | $73.99 M(+20.4%) | $73.99 M(-4.1%) |
| Sept 2017 | - | $77.14 M(+1.6%) |
| June 2017 | - | $75.94 M(+20.3%) |
| Mar 2017 | - | $63.15 M(+2.8%) |
| Dec 2016 | $61.45 M(-18.0%) | $61.45 M(+20.7%) |
| Sept 2016 | - | $50.91 M(-0.8%) |
| June 2016 | - | $51.30 M(-31.8%) |
| Mar 2016 | - | $75.22 M(+0.4%) |
| Dec 2015 | $74.94 M(+5.3%) | $74.94 M(-5.0%) |
| Sept 2015 | - | $78.90 M(+8.5%) |
| June 2015 | - | $72.70 M(+67.0%) |
| Mar 2015 | - | $43.52 M(-38.9%) |
| Dec 2014 | $71.19 M(+44.3%) | $71.19 M(+85.1%) |
| Sept 2014 | - | $38.47 M(-30.5%) |
| June 2014 | - | $55.36 M(+11.7%) |
| Mar 2014 | - | $49.57 M(+0.5%) |
| Dec 2013 | $49.33 M(-51.3%) | $49.33 M(-4.3%) |
| Sept 2013 | - | $51.53 M(+6.1%) |
| June 2013 | - | $48.57 M(-18.5%) |
| Mar 2013 | - | $59.63 M(-41.1%) |
| Dec 2012 | $101.29 M(+35.7%) | $101.29 M(+21.0%) |
| Sept 2012 | - | $83.73 M(+41.1%) |
| June 2012 | - | $59.35 M(-18.9%) |
| Mar 2012 | - | $73.23 M(-1.9%) |
| Dec 2011 | $74.64 M(+108.2%) | $74.64 M(+51.6%) |
| Sept 2011 | - | $49.25 M(-26.8%) |
| June 2011 | - | $67.28 M(+92.9%) |
| Mar 2011 | - | $34.88 M(-2.7%) |
| Dec 2010 | $35.85 M(-3.1%) | $35.85 M(+45.5%) |
| Sept 2010 | - | $24.64 M(-47.0%) |
| June 2010 | - | $46.49 M(+59.7%) |
| Mar 2010 | - | $29.12 M(-21.3%) |
| Dec 2009 | $36.99 M(-28.5%) | $36.99 M(+85.3%) |
| Sept 2009 | - | $19.96 M(-27.4%) |
| June 2009 | - | $27.49 M(+21.1%) |
| Mar 2009 | - | $22.70 M(-56.1%) |
| Dec 2008 | $51.76 M | $51.76 M(+64.5%) |
| Sept 2008 | - | $31.46 M(-13.4%) |
| June 2008 | - | $36.34 M(+16.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $31.28 M(-4.5%) |
| Dec 2007 | $32.75 M(+113.1%) | $32.75 M(+27.1%) |
| Sept 2007 | - | $25.76 M(+45.1%) |
| June 2007 | - | $17.75 M(+94.2%) |
| Mar 2007 | - | $9.14 M(-40.5%) |
| Dec 2006 | $15.37 M(+147.5%) | $15.37 M(+115.1%) |
| Sept 2006 | - | $7.14 M(-13.7%) |
| June 2006 | - | $8.28 M(+32.2%) |
| Mar 2006 | - | $6.26 M(+0.8%) |
| Dec 2005 | $6.21 M(-6.8%) | $6.21 M(-3.9%) |
| Sept 2005 | - | $6.46 M(-31.5%) |
| June 2005 | - | $9.43 M(+11.3%) |
| Mar 2005 | - | $8.47 M(+27.2%) |
| Dec 2004 | $6.66 M(-45.9%) | $6.66 M(-29.9%) |
| Sept 2004 | - | $9.50 M(+21.6%) |
| June 2004 | - | $7.82 M(+1.0%) |
| Mar 2004 | - | $7.74 M(-37.1%) |
| Dec 2003 | $12.31 M(-26.5%) | $12.31 M(+52.5%) |
| Sept 2003 | - | $8.07 M(-12.9%) |
| June 2003 | - | $9.27 M(-7.3%) |
| Mar 2003 | - | $10.00 M(-40.3%) |
| Dec 2002 | $16.75 M(+44.0%) | $16.75 M(+37.6%) |
| Sept 2002 | - | $12.17 M(+24.6%) |
| June 2002 | - | $9.76 M(-10.5%) |
| Mar 2002 | - | $10.91 M(-6.1%) |
| Dec 2001 | $11.63 M(+37.8%) | $11.63 M(+82.3%) |
| Sept 2001 | - | $6.38 M(+0.2%) |
| June 2001 | - | $6.36 M(+145.1%) |
| Mar 2001 | - | $2.60 M(-69.2%) |
| Dec 2000 | $8.44 M(-40.4%) | $8.44 M(-73.1%) |
| Sept 2000 | - | $31.39 M(+77.9%) |
| June 2000 | - | $17.64 M(+28.2%) |
| Mar 2000 | - | $13.77 M(-2.7%) |
| Dec 1999 | $14.15 M(+405.4%) | $14.15 M(+33.5%) |
| Sept 1999 | - | $10.60 M(-9.4%) |
| June 1999 | - | $11.70 M(+5.4%) |
| Mar 1999 | - | $11.10 M(+296.4%) |
| Dec 1998 | $2.80 M(-33.3%) | $2.80 M(-66.3%) |
| Sept 1998 | - | $8.30 M(+38.3%) |
| June 1998 | - | $6.00 M(-3.2%) |
| Mar 1998 | - | $6.20 M(+47.6%) |
| Dec 1997 | $4.20 M(+200.0%) | $4.20 M(-50.6%) |
| Sept 1997 | - | $8.50 M(+57.4%) |
| June 1997 | - | $5.40 M(-14.3%) |
| Mar 1997 | - | $6.30 M(+350.0%) |
| Dec 1996 | $1.40 M(-53.3%) | $1.40 M(-51.7%) |
| Sept 1996 | - | $2.90 M(-29.3%) |
| June 1996 | - | $4.10 M(-2.4%) |
| Mar 1996 | - | $4.20 M(+40.0%) |
| Dec 1995 | $3.00 M(+114.3%) | $3.00 M(-47.4%) |
| Sept 1995 | - | $5.70 M(-1.7%) |
| June 1995 | - | $5.80 M(+61.1%) |
| Mar 1995 | - | $3.60 M(+157.1%) |
| Dec 1994 | $1.40 M(-60.0%) | $1.40 M(-65.9%) |
| Sept 1994 | - | $4.10 M(+13.9%) |
| June 1994 | - | $3.60 M(+28.6%) |
| Mar 1994 | - | $2.80 M(-20.0%) |
| Dec 1993 | $3.50 M(+400.0%) | $3.50 M(+29.6%) |
| Sept 1993 | - | $2.70 M(+42.1%) |
| June 1993 | - | $1.90 M(-24.0%) |
| Mar 1993 | - | $2.50 M(+257.1%) |
| Dec 1992 | $700.00 K(-12.5%) | $700.00 K(-41.7%) |
| June 1992 | - | $1.20 M(+20.0%) |
| Mar 1992 | - | $1.00 M(+25.0%) |
| Dec 1991 | $800.00 K | $800.00 K(-11.1%) |
| Sept 1991 | - | $900.00 K(0.0%) |
| June 1991 | - | $900.00 K |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual accounts payable?
- What is the all time high annual accounts payable for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual accounts payable year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly accounts payable?
- What is the all time high quarterly accounts payable for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly accounts payable year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual accounts payable?
The current annual accounts payable of VRTX is $364.90 M
What is the all time high annual accounts payable for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual accounts payable is $364.90 M
What is Vertex Pharmaceuticals Incorporated annual accounts payable year-on-year change?
Over the past year, VRTX annual accounts payable has changed by +$61.00 M (+20.07%)
What is Vertex Pharmaceuticals Incorporated quarterly accounts payable?
The current quarterly accounts payable of VRTX is $395.80 M
What is the all time high quarterly accounts payable for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly accounts payable is $395.80 M
What is Vertex Pharmaceuticals Incorporated quarterly accounts payable year-on-year change?
Over the past year, VRTX quarterly accounts payable has changed by +$19.90 M (+5.29%)